For decades, the KRAS gene—a master regulator of cellular growth—was considered the "holy grail" of oncology, yet...
Chemotherapy and Targeted Therapy
In the high-stakes world of biopharmaceutical manufacturing, the transition from clinical-scale development to commercial-grade production is often...
In a move set to reshape the landscape of oral drug delivery, AustinPx—a Texas-based contract development and...
The pharmaceutical landscape is currently defined by a high-stakes convergence of aggressive litigation, landmark clinical trial results,...
By Ben Fidler, BioPharma Dive Published July 23, 2026 In a move that has sent shockwaves through...
In the high-stakes world of oncology, time is the most precious currency. For patients, it is the...
In a decisive move that underscores its aggressive pivot toward the oncology sector, British pharmaceutical giant GSK...
The Trump administration’s aggressive use of trade policy as a lever for domestic industrial policy has entered...
By Ben Fidler | July 21, 2026 In the high-stakes theater of modern venture capital, few firms...
In less than a decade, the therapeutic landscape of metabolic medicine has been fundamentally rewritten. What began...
